Across TCGA pan-cancer cohorts, SLC29A3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SLC29A3 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SLC29A3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC29A3 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where SLC29A3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.254	0.966	.001	19	view →
LUAD	DFS	Median	II,III,IV	0.198	0.785	.002	14	view →
PDAC	OS	Median	All	1.000	0.777	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: SLC29A3 tumor-vs-normal RNA expression · all SLC29A3 data types